Repeat BCG vaccination
Academic (Massachusetts General Hospital / collaborators)
Repeated Bacillus Calmette-Guerin vaccination repurposed as immune/metabolic therapy for established T1D. The long-running phase 2 adult and pediatric trials are now closed to enrolment but do not report until 2029 and 2031; a June 2026 systematic review found the published evidence still split between supportive and opposing studies. Intriguing but unproven, and not practice-changing.
The scorecard
BCG is proposed to alter autoreactive immunity and metabolism, but established-T1D trials focus more on HbA1c/glucose than clear C-peptide preservation.[1]
The strongest reported signal is delayed but persistent HbA1c lowering in small long-term cohorts; randomized confirmation remains pending. A June 2026 systematic review covering the literature to May 2026 still splits the evidence into supportive and opposing camps — nothing has resolved it.[4]
BCG is an old vaccine with broad human experience, but repeated use as T1D immunotherapy still requires trial safety confirmation.[2]
Trials include established adult and pediatric T1D, broader than many new-onset-only immunotherapies, though still research-only.[2]
Both Massachusetts General phase 2 trials (adult and pediatric, 150 participants each) are now closed to new enrolment but do not reach primary completion until July 2029 and March 2031 — a definitive randomized answer is years away, and there is no regulator-approved T1D indication.[1]
The full picture
BCG is one of the stranger long-running T1D hypotheses: an old tuberculosis vaccine used repeatedly to reshape immune and metabolic function. The appeal is access and safety; the problem is evidence certainty. Small long-term reports suggested delayed HbA1c improvement,1 but the field still needs rigorous randomized readouts to know whether this is real, reproducible, and clinically meaningful.
Where it stands, July 2026
Nothing has been settled. A systematic review published in June 2026, which searched the literature through May 2026, sorted the published work into studies that support a beneficial BCG effect in diabetes and studies that oppose it, called the findings highly heterogeneous, and concluded that the hypothesis remains unproven pending large randomized trials.2 That is an unusually blunt summary, and it matches how we score this record: interesting mechanism, thin and contested evidence.
The two Massachusetts General Hospital phase 2 trials — one in adults, one in children, 150 participants each — are now closed to new enrolment. But closed to enrolment is not the same as answered: primary completion is scheduled for July 2029 (adults) and March 2031 (children).34 A definitive randomized readout is years away.
One caution for anyone reading BCG headlines: there has been secondary press claiming a BCG trial cut insulin use in T1D. We could not trace that to a published paper or a primary trial report, so it is not reflected here. Until data are published and reviewable, treat such claims as unverified.
References
-
Long-term reduction in hyperglycemia in advanced type 1 diabetes after BCG vaccination — npj Vaccines, 21 June 2018. ↩
-
BCG vaccination as an adjunctive strategy in type 1 diabetes: a systematic review of immunometabolic effects and clinical evidence — Pathology, Research and Practice, 18 June 2026. ↩
-
Repeat BCG vaccinations for established type 1 diabetes (NCT02081326) — ClinicalTrials.gov. ↩
-
Repeat BCG vaccinations for pediatric type 1 diabetes (NCT05180591) — ClinicalTrials.gov. ↩
Coming soon
ETA · Phase 2 adult and pediatric trials are closed to enrolment but do not reach primary completion until 2029 and 2031. No approval timeline.
Sources
- [1]Repeat BCG vaccinations for established type 1 diabetes (NCT02081326) · registry
- [2]Repeat BCG vaccinations for pediatric type 1 diabetes (NCT05180591) · registry
- [3]Long-term reduction in hyperglycemia in advanced type 1 diabetes after BCG vaccination · peer-reviewed · 2018-06-21
- [4]BCG vaccination as an adjunctive strategy in type 1 diabetes: a systematic review of immunometabolic effects and clinical evidence · peer-reviewed · 2026-06-18 — Pathology, Research and Practice, 2026. Literature searched to May 2026; explicitly divides the evidence into studies supporting and studies opposing a beneficial BCG effect in T1D, and concludes the hypothesis remains unproven pending large randomized trials.